MERIT

Mutanome Engineered RNA Immuno-Therapy

Coordinatore	BIONTECH AG    more  Organization address address: HOLDERLINSTRASSE 8 city: Mainz postcode: 55131 contact info Titolo: Prof. Nome: Ugur Cognome: Sahin Email: send email Telefono: +49 613157627014 Fax: +49 613157627028
Nazionalità Coordinatore	Germany [DE]
Sito del progetto	http://merit-consortium.eu
Totale costo	7˙794˙995 €
EC contributo	5˙964˙250 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-2
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-06-01   -   2016-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	BIONTECH AG  Organization address address: HOLDERLINSTRASSE 8 city: Mainz postcode: 55131 contact info Titolo: Prof. Nome: Ugur Cognome: Sahin Email: send email Telefono: +49 613157627014 Fax: +49 613157627028	DE (Mainz)	coordinator	4˙456˙750.00
2	INSTITUT GUSTAVE ROUSSY  Organization address address: Rue Camille Desmoulins 39 city: VILLEJUIF postcode: 94805 contact info Titolo: Mr. Nome: Arnauld Cognome: Forest Email: send email Telefono: 33142116604 Fax: +33 142116160	FR (VILLEJUIF)	participant	453˙750.00
3	VRIJE UNIVERSITEIT BRUSSEL  Organization address address: PLEINLAAN 2 city: BRUSSEL postcode: 1050 contact info Titolo: Mr. Nome: Nik Cognome: Claesen Email: send email Telefono: 3226292210 Fax: 3226293640	BE (BRUSSEL)	participant	401˙250.00
4	UPPSALA UNIVERSITET  Organization address address: SANKT OLOFSGATAN 10 B city: UPPSALA postcode: 751 05 contact info Titolo: Mrs. Nome: Pirkko Cognome: Boox Email: send email Telefono: +46 18 471 4815 Fax: +46 18 471 4808	SE (UPPSALA)	participant	337˙500.00
5	UNIVERSITAET ZUERICH  Organization address address: Raemistrasse 71 city: ZURICH postcode: 8006 contact info Titolo: Dr. Nome: Steve Cognome: Pascolo Email: send email Telefono: +41 44 63 42877 Fax: +4144 63 42872	CH (ZURICH)	participant	315˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The Mutanome Engineered RNA Immuno-Therapy (MERIT) project aims to clinically translate and industrially validate a pioneering RNA-based immunotherapy approach to target the individual tumour antigen signature. MERIT focuses on previous inventions, fits into the overall business and innovation needs of the partners, and addresses triple-negative breast cancer patients with high medical need. The MERIT concept, including patents and potential products, was developed using EU FP6 funding. The innovative therapeutics will pave the way for generation of scientific knowledge and technologies and will stimulate the development of new products, tools, patents, and innovative marketable applications. The concept behind MERIT is to implement a highly innovative Next-Generation-Immunotherapy drug platform enabling Next–Generation-Sequencing-guided stratified medicine and clinical-grade individualized RNA vaccines. Every patient’s tumour expresses many shared tumour-specific antigens and bears a highly individual molecular “signature” comprising 10’s to 100’s of non-synonymous mutations, many of which are immunogenic. We will use clinical-grade RNA to produce a) a warehouse of therapeutic vaccines targeting shared antigens and b) custom therapeutic vaccines targeting patient-specific mutations. Upon success, partner BioNTech will move the therapeutics to advanced clinical trials and commercial applications for the benefit of triple negative breast cancer patients and other solid tumours.'